JPRN-UMIN000036862已完成4 期
Switching from cinacalcet to ebocalcet in secondary hyperparathyroidism patients during hemodialysis. - Switching from cinacalcet to ebocalcet
Fujita Memorial Hospita, Department of Internal Medicine0 个研究点目标入组 20 人开始时间: 2019年7月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
After changing from cinacalcet to evocalcet, there was no change in parathyroid hormone around 11 months. There were no serious adverse events during the study.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with malignant tumors
研究者
相似试验
已完成
4 期
Switching test from cinalcalcet to etelcalcetide in secondary hyperpapathyroidism patients ongoing hemodialysisSecondary hyperpapathyroidismJPRN-UMIN000033514Fujita Memorial Hospital, Department of Internal Medicine52
已完成
不适用
Prescription change from cinacalcet hydrochloride to evocalcet in hemodialysis patientsChronic hemodialysis patients with secondary hyperparathyroidismJPRN-UMIN000036702Kidney Disease and Dialysis Center, Hidaka Hospital, Hidaka-kai147
招募中
不适用
Switching from etelcalcetide to evocalcet in hemodialysis patients with secondary hyperparathyroidismSecondary hyperparathyroidismJPRN-UMIN000033856Jinken Clinic20
已完成
不适用
Clinical efficacy of intravenous calcium-sensing receptor agonist (etelcalcetide hydrochloride) for secondary hyperparathyroidismEnd-stage renal diseaseJPRN-UMIN000027408Saitama Tsukinomori Clinic32
已完成
2 期
PTH-independent Effects of EncaleretPost-Surgical HypoparathyroidismNCT05735015National Institute of Dental and Craniofacial Research (NIDCR)13